

Assessing insomnia after stroke: a diagnostic validation of the Sleep Condition Indicator in self-reported stroke survivors

Declan M McLaren ¹, Jonathan Evans,² Satu Baylan ,^{2,3,4} Monika Harvey,¹ Megan C Montgomery,⁵ Maria Gardani⁴

To cite: McLaren DM, Evans J, Baylan S, *et al.* Assessing insomnia after stroke: a diagnostic validation of the Sleep Condition Indicator in self-reported stroke survivors. *BMJ Neurology Open* 2024;**6**:e000768. doi:10.1136/bmjno-2024-000768

► Additional supplemental material is published online only. To view, please visit the journal online (<https://doi.org/10.1136/bmjno-2024-000768>).

Received 25 May 2024
Accepted 09 October 2024



© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

¹School of Psychology & Neuroscience, University of Glasgow, Glasgow, UK

²School of Health & Wellbeing, University of Glasgow, Glasgow, UK

³Regional Neuropsychology Service, NHS Greater Glasgow and Clyde, Glasgow, UK

⁴School of Health in Social Science, The University of Edinburgh, Edinburgh, UK

⁵The Oxford Institute for Clinical Psychology Training and Research, University of Oxford, Oxford, UK

Correspondence to
Dr Maria Gardani;
mgardani@ed.ac.uk

ABSTRACT

Background Insomnia is common after stroke and is associated with poorer recovery and greater risk of subsequent strokes. Yet, no insomnia measures have been validated in English-speaking individuals affected by stroke.

Aims This prospective diagnostic validation study investigated the discriminatory validity and optimal diagnostic cut-off of the Sleep Condition Indicator when screening for Diagnostic and Statistical Manual of Mental Disorders—fifth edition (DSM-5) insomnia disorder post-stroke.

Methods A convenience sample of 180 (60.0% women, mean age=49.61 ± 12.41 years) community-based, adult (≥18 years) self-reported stroke survivors completed an online questionnaire. Diagnosis of DSM-5 insomnia disorder was based on analysis of a detailed sleep history questionnaire. Statistical analyses explored discriminant validity, convergent validity, relationships with demographic and mood variables, and internal consistency. Receiver operating characteristic curves were plotted to assess diagnostic accuracy.

Results Data from the sleep history questionnaire suggested that 75 participants (41.67%) met criteria for DSM-5 insomnia disorder, 33 (18.33%) exhibited symptoms of insomnia but did not meet diagnostic criteria, and 72 (40.0%) had no insomnia symptoms at the time of assessment. The Sleep Condition Indicator (SCI) demonstrated ‘excellent’ diagnostic accuracy in the detection of insomnia post-stroke, with an area under the curve of 0.86 (95% CI (0.81, 0.91)). The optimal cut-off was determined as being ≤13, yielding a sensitivity of 88.0% and a specificity of 71.43%.

Conclusions The findings of this study demonstrate the SCI to be a valid and reliable method with which to diagnose DSM-5 insomnia disorder and symptoms post-stroke. However, a lower threshold than is used in the general population may be necessary after stroke.

INTRODUCTION

A growing body of evidence indicates a bi-directional relationship between sleep and stroke.¹ Insomnia, broadly defined as difficulty with initiating, maintaining or returning to sleep, which impacts daily functioning, is

WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ Several meta-analyses have demonstrated the prevalence of insomnia after stroke to be higher than that found in the general population. However, currently, no insomnia measure has been validated for use in English-speaking individuals who have had a stroke.

WHAT THIS STUDY ADDS

⇒ This is the first diagnostic validation of a diagnostic measure for insomnia in a sample of English-speaking stroke survivors.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ The findings confirm the validity of the Sleep Condition Indicator post-stroke indicating a threshold of ≤13 to be most optimal. Use of the conventional threshold of ≤16 would lead to an inflated false-positive rate.

estimated to affect 32.21% to 50.4% of people affected by stroke; although estimates vary depending on diagnostic criteria and phase of recovery.^{2–3} Prior to an individual’s first stroke, insomnia symptoms are associated with a 30% increased risk of stroke⁴; and post-stroke are associated with poorer functional and cognitive outcomes,⁵ and psychological distress.⁶ Correspondingly, clinical guidelines and stroke organisations encourage post-stroke sleep assessment^{7–8} to facilitate stroke management and reduce the risk of recurrence.

With respect to the assessment and diagnosis of insomnia disorder in the general population, the use of clinical interviews investigating an individual’s sleep history is recommended.⁹ Psychometric tools commonly comprise part of this process, yet diagnostic validations of insomnia measures post-stroke have only recently been conducted. Chinese translations of the Insomnia Severity Index,

Pittsburgh Sleep Quality Index and Athens Insomnia Scale have demonstrated ‘outstanding’ diagnostic accuracy post-stroke.¹⁰ However, none of these measures sufficiently capture the diagnostic criteria for insomnia disorder detailed in the Diagnostic and Statistical Manual of Mental Disorders—fifth edition (DSM-5).¹¹

A valid diagnosis is dependent on specific diagnostic criteria,⁹ with which a scale intended for clinical use should be aligned. The Sleep Condition Indicator¹² is a short self-report questionnaire, designed to screen for insomnia disorder in accordance with DSM-5 criteria.¹¹ A recent validation of the Indonesian translation of the Sleep Condition Indicator (SCI)¹³ suggested the tool was valid for use post-stroke but recommended using a higher diagnostic threshold of ≤ 23 rather than ≤ 16 used in the general population.^{12 14} However, existing validations of SCI translations do demonstrate heterogeneity in estimates of optimal cut-offs,^{15–18} suggesting possible confounds from translation and/or nuanced cultural differences.

Accurate diagnoses are inextricably linked to appropriate treatment. Thus, a scale intended for clinical or research use must be able to discriminate accurately between individuals with and without the condition of interest. Therefore, this study investigated the discriminant validity and optimal threshold of the English language SCI when detecting insomnia disorder, and symptoms, in a sample of self-reported stroke survivors. Secondary objectives involved assessing convergent validity, examining relationships between the SCI and variables relating to mood and general demographics, and assessing the internal consistency of the SCI after stroke. Additionally, we explored the discriminant validity, optimal threshold and internal validity of the SCI-2,¹⁹ a two-item version of the SCI comprised of items 3 and 7 from the full scale.

MATERIALS AND METHODS

The pre-registered protocol for this cross-sectional prospective diagnostic validation study can be found at: <https://doi.org/10.17605/OSF.IO/4DGXW>.

Participants and recruitment

Using voluntary response sampling via social media (Twitter/X, Instagram, Facebook, Reddit), community-based adult (≥ 18 years) stroke survivors were recruited across the UK from June 2022 to October 2023. Participants experiencing jetlag (crossed ≥ 2 time zones in the week preceding participation), undergoing treatment(s) that may affect their sleep (eg, cancer treatment) or working nightshifts were excluded. Participants were not asked to describe whether they had experienced a haemorrhagic or ischaemic stroke to avoid the risk of individuals self-excluding due to not knowing or remembering this information. Consent was obtained electronically, and no compensation was provided for participation. Responses were anonymous, and participants had the option of sharing their email addresses for future contact by the

research team. Email addresses could not be linked to survey responses.

Ethical favourable opinion

A favourable ethical opinion was obtained from the University of Glasgow College of Science and Engineering Research Ethics Committee (#300210126). Optional aphasia friendly materials were available to all participants via a link on the participant information page (see online supplemental material 1).

Sample size estimation

An a priori power analysis was conducted using the ‘MKPower’ package.²⁰ Initial calculations were performed using parameters obtained from the existing literature. Expected prevalence was set to 32%, as estimated in Baylan *et al*,² and expected sensitivity was set to 89%, estimated by averaging the results of four existing validations of the Sleep Condition Indicator which used the conventional cut-off of ≤ 16 .^{12 15 21 22} To achieve a statistical power of 0.8, with $\alpha=0.05$, and δ (delta)=0.1, the required sample size was 316. Following data collection from the first 109 participants, sample size estimations were re-evaluated due to stroke-specific parameters being made available in Hasan *et al*.¹³ Expected sensitivity was set to 94%¹³ and expected prevalence to 40.37% (taken from the actual prevalence in the preliminary data). With all other parameters unchanged, the estimated sample size required to achieve 80% statistical power was 176.

Measures and materials

Participants completed an online survey comprising questionnaires pertaining to sleep, mental health and stroke. Demographic information was also collected and comprised age, gender, time since most recent stroke, side of body affected by stroke, and total number of strokes. The index test being evaluated in this study was the SCI,¹² total scores of which range from 0 to 32, with scores ≤ 16 considered indicative of insomnia disorder in the general population.^{12 14} The validity of a two-item variant (SCI-2)¹⁹ was also examined. Reference standard classifications of DSM-5 ‘Insomnia disorder’, ‘Insomnia symptoms’ or ‘no insomnia’ were made following review of a comprehensive sleep history questionnaire,²³ for use in people following Acquired Brain Injury, adapted for use online by people after stroke. Index and reference tests were completed consecutively. Participants were classified as having ‘insomnia disorder’ if they reported difficulties with initiating or maintaining sleep, or early morning awakening, for at least three nights per week, which caused distress or impairment throughout the day, and symptoms had persisted for at least 3 months. Participants were classified as having ‘Insomnia symptoms’ if they displayed symptoms of insomnia but did not meet DSM-5 thresholds for severity, duration or frequency, or their symptoms were likely to be better explained by another sleep disorder.¹¹

Convergent validity was assessed by exploring correlations between the SCI and the Insomnia Severity Index (ISI),²⁴ a 7-item insomnia measure, scored from 0 to 28 with higher scores denoting greater insomnia severity. A Chinese translation of the ISI was recently validated for use after stroke.¹⁰

Depression was measured via the Patient Health Questionnaire (PHQ-9),²⁵ a 9-item self-report scale scored from 0 to 27, where greater scores denote greater severity of depressive symptoms. Anxiety was measured via the Generalised Anxiety Disorder Scale (GAD-7),²⁶ a 7-item self-report measure scored from 0 to 21, where greater scores denote greater severity of anxious symptoms. Stroke severity was assessed via the Stroke Impact Scale Short Form (SIS-SF),²⁷ an 8-item self-report score scored from 8 to 40, where lower scores denote greater severity of impact from stroke.

Data were collected via an online survey platform (<https://www.qualtrics.com/>). Classifications were determined by two researchers (DM, MM) independently, blind to SCI scores, following calibration of scoring by MG on five responses. Per cent agreement between assessor classifications was computed for the first 25 participants, with 100% agreement attained.

Statistical analyses

Statistical analyses were conducted using R (V.4.3.1). Forced responses prevented missing values on the sleep history questionnaire and the SCI. Missing data from other scales (GAD-7, PHQ-9, SIS-SF, ISI) or demographic information were omitted in their respective analyses. As surveys could be completed across multiple sessions, mean durations greater than 1.5× the interquartile range (n=18) were omitted when calculating summary statistics to curtail the impact of outlier effects.

Normality was assessed visually and with Anderson-Darling tests. Descriptive analysis of demographic and psychometric variables was conducted across classifications. Kruskal-Wallis tests were used for group comparisons of continuous variables, and Dunn's tests with Bonferroni corrections used for pairwise comparisons. Group differences in categorical data were explored using Fisher's exact test. Statistical significance was set at $p < 0.05$. Spearman's correlations were used to quantify relationships between the SCI and continuous variables, and CIs were computed via bootstrapping (n=1000). The internal consistency of all psychometric scales was assessed via Cronbach's α ,²⁸ and the commonly assumed threshold of ≥ 0.70 adopted to indicate acceptable reliability.²⁹

Receiver operating characteristic (ROC) curves were plotted using the 'pROC' package³⁰ to assess the SCI's diagnostic accuracy. Youden's J statistic³¹ was calculated to determine the optimal diagnostic cut-off. The area under the curve (AUC) provided an estimate of overall accuracy. AUC values of 0.7 to 0.8 were considered 'acceptable', 0.8 to 0.9 'excellent', and > 0.9 'outstanding' diagnostic accuracy.³² CIs were computed via bootstrapping (n=2000).

RESULTS

Participant characteristics

A total of 544 potential participants accessed the study platform (see figure 1), of which 246 exited before providing consent, and 118 did not complete the SCI and/or sleep history. The remaining 180 provided consent and all met inclusion criteria. The mean survey duration was 24.48 min (SD=10.56). Participant characteristics are summarised in table 1.

After classification based on the sleep history, 75 (41.67%) participants met criteria for insomnia disorder, 33 (18.33%) exhibited insomnia symptoms without meeting diagnostic criteria and 72 (40.0%) had no insomnia symptoms. A breakdown of participants by classification is available in figure 1 (a confusion matrix of index vs reference standard classifications can be found in the online supplemental material 2).

The distribution of total SCI scores by classification is displayed in figure 2. Skewness and kurtosis were 0.40 and 2.46, respectively. Visual inspection and Anderson-Darling tests ($p=0.004$) indicated non-normal distribution of total SCI scores.

Sensitivity and specificity of the SCI

When detecting insomnia disorder post-stroke using the SCI, the AUC was 0.86 (95% CI (0.81, 0.91); figure 3), with an optimal cut-off of ≤ 13 , yielding sensitivity, specificity and Youden's J values of 88.0%, 71.43% and 0.59, respectively (see table 2). When detecting insomnia symptoms, the AUC was 0.85 (95% CI (0.80, 0.91); figure 3), with an optimal cut-off of ≤ 14 , yielding sensitivity, specificity and Youden's J values of 81.48%, 76.39% and 0.58, respectively (see table 2). Both AUC curves are indicative of 'excellent' diagnostic accuracy.³² Delong's test for two paired ROC curves found no statistical difference ($p=0.91$) in the SCI's ability to detect insomnia disorder vs symptoms. Using the sensitivity observed when detecting insomnia disorder, with all other parameters unchanged, returns a power of 0.71.

Sensitivity and specificity of the SCI-2

ROC analysis was performed on the summed totals for items 3 and 7 of the SCI (figure 4), forming the SCI-2.¹⁹ When detecting DSM-5 insomnia in stroke survivors, the AUC for the SCI-2 was 0.79 (95% CI (0.73, 0.85)), with an optimal cut-off of ≤ 2 . Corresponding with a specificity of 68.57%, sensitivity of 76.0% and a Youden's J of 0.45. Delong's test provided statistical evidence ($p < 0.001$) that the SCI outperformed the SCI-2. Sensitivity and specificity values at all thresholds can be found in online supplemental material 4. The positive and negative predictive values of the SCI in this sample, using the optimal threshold of ≤ 13 , were 0.69 and 0.89, respectively. Predictive values at a range of hypothetical prevalence rates can be found in online supplemental material 5.




Figure 1 Participant flowchart.

Convergent validity

Spearman's rank correlation was computed to assess the relationship between total scores on the ISI and SCI, with ties handled by average ranks. Results revealed a large negative correlation between the two scales ($r(178) = -0.86$, 95% CI $(-0.91, -0.80)$; [figure 5](#)).

Associations between the SCI, demographic, stroke, and mood variables

Spearman's rho was computed to determine the strength of the relationship between total SCI scores and all other continuous variables. Results are presented in [table 3](#).

Internal validity

The reliability of all included psychometric scales was assessed via Cronbach's α , and all deemed acceptable. For the SCI ($n=180$), Cronbach's α was 0.84 (95% CI $(0.80, 0.87)$); for the SCI-2 ($n=180$), α was 0.76 (95% CI $(0.69, 0.82)$); for the GAD-7 ($n=179$), α was 0.91 (95% CI $(0.89, 0.93)$); for the PHQ-9 ($n=179$), α was 0.89

(95% CI $(0.87, 0.92)$); and for the SIS-SF ($n=178$), α was 0.83 (95% CI $(0.78, 0.86)$).

DISCUSSION

This is the first study examining the SCI's validity and reliability, and that of any insomnia screening tool, in a sample of English-speaking stroke survivors. Results from 180 participants indicated that 41.7% met DSM-5 criteria for insomnia disorder, and 60.0% exhibited insomnia symptoms (including those classified as insomnia disorder), consistent with meta-analytic findings on post-stroke insomnia prevalence (2,3), and supporting the representativeness of the sample. The remaining 40% had no insomnia symptoms.

The SCI demonstrated 'excellent' diagnostic accuracy when screening for DSM-5 insomnia disorder (AUC=0.86) and/or symptoms (AUC=0.85) post-stroke. Moreover, examination of internal consistency indicated acceptable

Table 1 : Participant characteristics

| Variable | Total (n=180) Mean (SD) | Insomnia disorder (n=75) Mean (SD) | Insomnia symptoms (n=33) Mean (SD) | No insomnia (n=72) Mean (SD) | P value |
|---------------------------|-------------------------------|--|--|------------------------------------|----------------|
| Age | 49.61 (12.41) | 49.24 (12.04) | 51.82 (11.56) | 48.99 (13.18) | 0.689 |
| Depression (PHQ-9) | 10.80 (7.31) | 12.97 (7.36)* | 11.48 (7.53) | 8.20 (6.35)* | <0.001 |
| Anxiety (GAD-7) | 7.92 (6.19) | 9.83 (6.55)* | 7.06 (5.94) | 6.31 (5.40)* | 0.004 |
| Stroke Severity (SIS-SF) | 30.02 (6.40) | 29.00 (5.99)* | 28.97 (6.70) | 31.60 (6.46)* | 0.018 |
| Time since stroke (years) | 4.16 (4.26) | 3.81 (3.55) | 3.02 (3.72) | 5.09 (5.02) | 0.069 |
| SCI | 13.74 (7.51) | 8.47 (4.60)** | 13.52 (5.33) ^{+o} | 19.35 (6.79) ^o | <0.001 |
| ISI | 13.40 (6.59) | 17.68 (5.59) ^{o*} | 13.76 (4.31) ^{o+} | 8.78 (5.25)** | <0.001 |
| Variable | n (%) | n (%) | n (%) | n (%) | p value |
| Gender | | | | | 0.087 |
| Female | 108 (60.00) | 52 (69.33) | 15 (45.45) | 41 (56.94) | |
| Male | 70 (38.89) | 22 (29.33) | 18 (54.55) | 30 (41.67) | |
| Non-binary | 2 (1.11) | 1 (1.33) | 0 (0) | 1 (1.39) | |
| Number of strokes | | | | | 0.336 |
| 1 | 152 (84.44) | 62 (82.67) | 32 (96.97) | 58 (80.56) | |
| 2 | 22 (12.22) | 9 (12.00) | 1 (3.03) | 12 (16.67) | |
| 3 | 2 (1.11) | 1 (1.33) | 0 (0) | 1 (1.39) | |
| >3 | 4 (2.22) | 3 (4.00) | 0 (0) | 1 (1.39) | |
| Affected side | | | | | 0.994 |
| Don't remember | 20 (11.11) | 8 (10.67) | 3 (9.09) | 9 (12.50) | |
| Left | 84 (46.67) | 35 (46.67) | 16 (48.48) | 33 (45.83) | |
| Right | 76 (42.22) | 32 (42.67) | 14 (42.42) | 30 (41.67) | |

Statistically significant differences exist between groups that are marked by the same symbol on one row. One participant was excluded from SIS-SF, PHQ-9 and GAD-7 analyses, and another from SIS-SF analyses, due to incomplete data. Both were classified as 'No Insomnia'. GAD-7, Generalised Anxiety Disorder Scale; ISI, Insomnia Severity Index; n, number of participants; PHQ-9, Patient Health Questionnaire; SCI, Sleep Condition Indicator; SD, Standard deviation; SIS-SF, Stroke Impact Scale Short Form.

reliability (Cronbach's $\alpha=0.84$). The SCI-2 demonstrated 'acceptable' accuracy, with an optimal cut-off of ≤ 2 ; paralleling validations in the general population.¹⁹ However, the full SCI demonstrated significantly higher accuracy and should be the preferred assessment method where possible.

Estimates of diagnostic accuracy in the current study are similar, although slightly lower, to recent validations in stroke populations of the SCI in Indonesian¹³ and the Insomnia Severity Index, Pittsburgh Sleep Quality Index and Athens Insomnia Index in Chinese.¹⁰ Nonetheless, comparisons should be drawn cautiously. Existing validations of SCI translations demonstrate heterogeneity in estimates of optimal cut-offs,^{15–18} suggesting possible confounds from translation and/or nuanced cultural differences. Additionally, a recent meta-analysis demonstrated that condition prevalence may influence the sensitivity and specificity of binary diagnostic tests.³³ The prevalence of insomnia in the previous validations^{10 13} was 15.6% and 31.0%, respectively, both being lower than the current study (41.7%) and previous estimates of post-stroke insomnia prevalence.^{2 3} Thus, the variance in

prevalence should be considered when comparing studies of diagnostic accuracy, and when considering a screening tool for clinical or research use.

The optimal cut-off for detecting insomnia disorder using the SCI in the current study was found to be ≤ 13 . This is lower than both the conventional cut-off for the general population of ≤ 16 ,^{12 14} and the optimal cut-off of ≤ 23 observed in the validation of the Indonesian translation of the SCI post-stroke.¹³ Were the conventional cut-off adopted in the current sample, 96% of positive insomnia disorder cases would be correctly identified. However, approximately 45.7% of participants without insomnia disorder would be incorrectly classified as a positive case (ie, having insomnia disorder). Depending on the intended use for the scale, there may be instances where clinicians or researchers wish to maximise sensitivity at the expense of specificity (or vice versa) but should do so with caution. Use of an erroneously high threshold on the SCI will lead to an increased false-positive rate, potentially leading to inappropriate treatment and use of resources in clinical settings; and may cast doubt on the validity of findings in research.




Figure 2 Violin and boxplot graphs displaying the distribution of total SCI scores by classification. SCI, Sleep Condition Indicator.

Understanding the heterogeneity of optimal diagnostic thresholds is important for ensuring the SCI is appropriately used in different clinical samples, and future research should explore this further. One possibility is that poorer




Figure 3 ROC curves displaying the accuracy of the SCI when detecting Diagnostic and Statistical Manual of Mental Disorders—fifth edition (DSM-5) insomnia disorder and symptoms, including AUC values and 95% CIs. ROC, receiver operating characteristic; SCI, Sleep Condition Indicator; AUC, area under the curve.

sleep post-stroke³⁴ may necessitate a lower threshold. Mean SCI scores in the current study (\bar{x} = 13.74, SD=7.51) are slightly lower and display greater variance than results from a retrospective exploration of scores in 200 000 adults who completed the SCI (\bar{x} = 14.97, SD=5.93; 14). However, the results of the latter¹⁴ may be biased towards people with sleep impairment, and the true population mean SCI scores are likely higher. Variation in reference standards likely also contributes to variability in optimal cut-offs, and ideally studies seeking to validate measures of insomnia should select reference standards in accordance with guidelines on the assessment and diagnosis of insomnia disorder.⁹ In studies of diagnostic accuracy, the reference standard assumes infallibility. Yet, the index test may not always be solely responsible for the discrepancy.³⁵ The conventional cut-off of ≤ 16 ^{12 14} was determined as the minimum score necessary for putative DSM-5 insomnia disorder, with convergent validity assessed against the ISI. The ISI boasts commendable accuracy but standalone is not a recommended tool for diagnosing DSM-5 insomnia disorder⁹ and is less specific than clinical interviews. Thus, when comparing the optimal diagnostic cut-offs between studies, one should be cognisant of the possibility of differences in reference standards explaining some or all the variation in optimal cut-offs.

Spectrum bias, a phenomenon whereby accuracy of a diagnostic test may be confounded by symptom severity,³⁶ may further explain discrepancies in optimal diagnostic thresholds between studies. Scores closer to the cut-off are more prone to misclassification; therefore, studies where index test scores demonstrate a bimodal distribution have

Table 2 Sensitivity, specificity and Youden's J statistic for select thresholds on the SCI when detecting DSM-5 insomnia disorder and insomnia symptoms

| Insomnia disorder | | | | Insomnia disorder and symptoms | | | |
|-------------------|-----------------|-----------------|-------------|--------------------------------|-----------------|-----------------|-------------|
| Threshold | Specificity (%) | Sensitivity (%) | Youden's J | Threshold | Specificity (%) | Sensitivity (%) | Youden's J |
| 8 | 89.52 | 52.00 | 0.42 | 8 | 91.67 | 40.74 | 0.32 |
| 9 | 85.71 | 57.33 | 0.43 | 9 | 88.89 | 46.30 | 0.35 |
| 10 | 81.90 | 70.67 | 0.53 | 10 | 86.11 | 57.41 | 0.44 |
| 11 | 80.95 | 73.33 | 0.54 | 11 | 86.11 | 60.19 | 0.46 |
| 12 | 78.10 | 78.67 | 0.57 | 12 | 83.33 | 64.81 | 0.48 |
| 13 | 71.43 | 88.00 | 0.59 | 13 | 80.56 | 75.93 | 0.56 |
| 14 | 64.76 | 90.67 | 0.55 | 14 | 76.39 | 81.48 | 0.58 |
| 15 | 60.00 | 90.67 | 0.51 | 15 | 73.61 | 84.26 | 0.58 |
| 16 | 54.29 | 96.00 | 0.50 | 16 | 66.67 | 88.89 | 0.56 |
| 17 | 48.57 | 98.67 | 0.47 | 17 | 59.72 | 91.67 | 0.51 |

Values for all thresholds can be found in online supplemental material 3. Optimal thresholds are displayed in bold. Youden's J – (J = sensitivity + specificity – 1).

DSM-5, Diagnostic and Statistical Manual of Mental Disorders—fifth edition; SCI, Sleep Condition Indicator.

a greater risk of spectrum bias. Hasan *et al*¹³ excluded 164 participants with sleep or psychiatric disorders other than insomnia in their validation. Many of these participants would likely have scored lower on the SCI regardless of insomnia classification, as suggested by the relationships between SCI score and measures of mental health in the current study and corroborated by meta-analytic results from Hertenstein *et al*.³⁷ Likely as a result of their inclusion

criteria, mean SCI scores in Hasan *et al*¹³ for participants without insomnia were 29.55 (SD=1.96), with little variance. Compared with 19.33 (SD=6.81) in the current study, which is more akin to previous research.³⁴ Such a skewed distribution of scores allows specificity to remain high at higher thresholds, contributing to potentially misleading estimates of accuracy and optimal cut-offs. Hasan and colleagues demonstrate that the Indonesian SCI can discriminate post-stroke insomnia disorder in the absence of potential confounds. The present study adds to this by validating the English SCI in self-reported stroke survivors and doing so while including participants with comorbid psychological or sleep disorders; thereby increasing generalisability of the findings. Results of the current study, when considered in the context of the existing literature, highlight the importance of considering spectrum bias in studies of diagnostic accuracy. When considering a screening tool, researchers and clinicians should consider whether a study's selection criteria are clinically meaningful to the population they intend to use the test in.

This study has several strengths. A priori power analyses, a rarity in studies of diagnostic accuracy,³⁸ ensured the study was suitably powered to obtain reliable estimates of accuracy. Consecutive completion of index and reference tests reduced the risk of temporal changes in disease state. Finally, stratifying analyses by insomnia classification reduced the risk of spectrum bias and prevalence influencing estimates of accuracy.³³

Nonetheless, voluntary response sampling does carry a risk of response bias and may lead to over-representation of participants with an interest in sleep, or more severe sleep difficulties. However, prevalence in the current sample aligns with that of previous meta-analytic estimates.^{2 3} Recruiting participants via social media may have led to a younger than expected stroke sample (mean




Figure 4 ROC curves displaying the accuracy of the SCI-2 when detecting Diagnostic and Statistical Manual of Mental Disorders—fifth edition (DSM-5) insomnia disorder and symptoms, including AUC values and 95% CIs. ROC, receiver operating characteristic; AUC, area under the curve; SCI, Sleep Condition Indicator.




Figure 5 Scatter plot visualising the relationship between total SCI and Insomnia Severity Index (ISI) scores.

age=49.61 ± 12.41 years). Future research may wish to consult older stroke survivors to explore methods of increasing the accessibility of online stroke research to a wider age range. Nevertheless, stroke can affect people of any age, and research representative of younger stroke survivors is necessary, particularly to understand the challenges of improving life after stroke for working age individuals—perhaps with young families—compared with older adults. Results of a linear regression from a large cross-sectional study (n=200 000) by Espie and colleagues¹⁴ did demonstrate that SCI score was predicted to decrease 0.057 points per year of life. Findings from the current study demonstrated no significant relationship between age, or gender, and total SCI score; however, it is likely that a much larger sample size would be needed to detect an effect as small as that described in Espie *et al.*¹⁴ Thus, although the modulating effect of

demographic characteristics on the accuracy of the SCI was not explored, current findings provide no evidence to suggest that such an effect exists. Due to the online nature of recruitment, participant self-reports of stroke were not verified by another means. Various efforts were made, however, to minimise the risk of individuals without a history of stroke volunteering to take part. First, recruitment adverts were shared explicitly by stroke researchers and third sector organisations supporting stroke survivors, targeting stroke peer support groups. Moreover, offering no incentive to participants removed the risk of individuals taking part without a history of stroke for financial gain. Furthermore, while the results of a systematic review by Woodfield *et al.*⁸⁹ demonstrate that the sensitivity and positive predictive value of self-reported stroke is low in samples with low prevalence, specificity (96% to 99.1%) and negative predictive value (88.2% to 99.9%) were consistently high. As one would expect, authors report that positive predictive values increased in line with prevalence. Thus, in samples with high prevalence of stroke, such as in the current study, the risk of false positives is likely to be small. We therefore believe self-reports of stroke in the present sample to be reliable. Nevertheless, where time and resources allow, future researchers may wish to verify self-reported stroke status by recruiting participants from stroke outpatient clinics or obtaining clinical records. Moreover, the number of incomplete responses (n=118) is worth noting. This may indicate systemic challenges related to conducting stroke research online, or difficulties faced by potential participants with language difficulties. Relatedly, the duration of the survey was relatively long, and future research

Table 3 Spearman's correlation coefficients, CIs and p values for relationships between the SCI and select demographic and psychometric variables

| Variable | R | 95% CI | P value |
|-------------------|-------|----------------|---------|
| Age | −0.07 | (−0.20, 0.08) | 0.357 |
| PHQ-9 | −0.63 | (−0.72, −0.52) | <0.001 |
| GAD-7 | −0.47 | (−0.57, −0.33) | <0.001 |
| SIS-SF | 0.47 | (0.34, 0.57) | <0.001 |
| Time since stroke | 0.03 | (−0.12, 0.18) | 0.713 |

GAD-7, Generalised Anxiety Disorder Scale; PHQ-9, Patient Health Questionnaire; SCI, Sleep Condition Indicator; SIS-SF, Stroke Impact Scale Short Form.

may consider limiting survey length further to increase accessibility. Finally, participants were not asked which type of stroke they had. This was a methodological decision to avoid excluding participants who did not know or remember. Existing evidence does indicate potential relationships between insomnia and stroke type/location;⁴⁰ therefore, future researchers may wish to consider purposive sampling methods that allow exploration of whether these phenomena may influence insomnia presentation and the accuracy of diagnostic measures.

In summary, this study confirms the validity and reliability of the English version of the SCI when detecting DSM-5 insomnia in self-reported stroke survivors and indicates that a lower threshold than is traditionally used should be considered when using the SCI in the stroke population. At the optimal diagnostic threshold of ≤ 13 , the SCI demonstrates 'excellent' diagnostic accuracy. The brevity of the tool makes it attractive for clinical and research use and the SCI-2 does offer an acceptable shorter alternative. Nevertheless, the accuracy of the SCI-2 is outperformed by the full SCI, and use of the latter should be preferred where possible. In conclusion, the SCI should be considered a valid and reliable screening tool for DSM-5 insomnia disorder and insomnia symptoms post-stroke.

X Declan M McLaren @DNeuropsych

Acknowledgements The authors express their gratitude to the UK Stroke Association for their partnership in this study. We would also like to thank Same You and Headway for their support with recruitment. Appreciation is also extended to Professor Terry Quinn and the Glasgow Stroke User Group for their support.

Contributors DMM, MG, JE and SB contributed to the conceptualisation, methodology, resources and project administration. MG, JE, SB and MH additionally contributed to supervision of the project and funding acquisition. DMM led the visualisation, writing of the original draft, data curation, investigation, software and formal analysis. MCM assisted with the data curation and formal analysis. All authors contributed to the reviewing and editing of the manuscript and MG is guarantor.

Funding This research was funded by the Scottish Graduate School of Social Science (Award number: ES/P000681/1).

Competing interests No, there are no competing interests.

Patient consent for publication Not applicable.

Ethics approval This study involves human participants. Ethical approval was obtained from the University of Glasgow College of Science and Engineering Research Ethics Committee (#300210126). Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. Data are available upon reasonable request to the corresponding author.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially,

and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iDs

Declan M McLaren <http://orcid.org/0000-0001-7578-1698>

Satu Baylan <http://orcid.org/0000-0002-5887-315X>

REFERENCES

- Mayer-Suess L, Ibrahim A, Moelgg K, *et al*. Sleep disorders as both risk factors for, and a consequence of, stroke: A narrative review. *Int J Stroke* 2024;19:490–8.
- Baylan S, Griffiths S, Grant N, *et al*. Incidence and prevalence of post-stroke insomnia: A systematic review and meta-analysis. *Sleep Med Rev* 2020;49:101222.
- Hasan F, Gordon C, Wu D, *et al*. Dynamic Prevalence of Sleep Disorders Following Stroke or Transient Ischemic Attack: Systematic Review and Meta-Analysis. *Stroke* 2021;52:655–63.
- McCarthy CE, Yusuf S, Judge C, *et al*. Sleep Patterns and the Risk of Acute Stroke: Results From the INTERSTROKE International Case-Control Study. *Neurol (Echronicon)* 2023;100:e2191–203.
- Matas A, Amaral L, Patto AV. Is post-ischemic stroke insomnia related to a negative functional and cognitive outcome? *Sleep Med* 2022;94:1–7.
- Glozier N, Moullaali TJ, Sivertsen B, *et al*. The Course and Impact of Poststroke Insomnia in Stroke Survivors Aged 18 to 65 Years: Results from the Psychosocial Outcomes In Stroke (POISE) Study. *Cerebrovasc Dis Extra* 2017;7:9–20.
- National Institute for Health and Care Excellence. Secondary prevention following stroke and tia - nice clinical knowledge summaries. NICE Clinical Knowledge Summaries; 2023. Available: <https://cks.nice.org.uk/topics/stroke-tia/management/secondary-prevention-following-stroke-tia/> [Accessed 13 Jun 2023].
- Kernan WN, Ovbiagele B, Kittner SJ. Response to Letter Regarding Article, "Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association." *Stroke* 2015;46:2160–236.
- Riemann D, Espie CA, Altena E, *et al*. The European Insomnia Guideline: An update on the diagnosis and treatment of insomnia 2023. *J Sleep Res* 2023;32:e14035.
- Niu S, Wu Q, Ding S, *et al*. Comparison of three measures for insomnia in ischemic stroke patients: Pittsburgh sleep quality index, insomnia severity index, and Athens insomnia scale. *Front Neurol* 2023;14:1118322.
- American Psychiatric Association D 5 TF. *Diagnostic and Statistical Manual of Mental Disorders: DSM-5*. 5th edn. American Psychiatric Association, 2013.
- Espie CA, Kyle SD, Hames P, *et al*. The Sleep Condition Indicator: a clinical screening tool to evaluate insomnia disorder. *BMJ Open* 2014;4:e004183.
- Hasan F, Vidyanti AN, Tsai P-S, *et al*. Psychometric properties of Indonesian version of sleep condition indicator for screening poststroke insomnia. *S B* 2023;27:2013–20.
- Espie CA, Farias Machado P, Carl JR, *et al*. The Sleep Condition Indicator: reference values derived from a sample of 200 000 adults. *J Sleep Res* 2018;27:e12643.
- Bayard S, Lebrun C, Maudarbocus KH, *et al*. Validation of a French version of the Sleep Condition Indicator: a clinical screening tool for insomnia disorder according to DSM-5 criteria. *J Sleep Res* 2017;26:702–8.
- Palagini L, Ragnio G, Caccavale L. Italian validation of the Sleep Condition Indicator: A clinical screening tool to evaluate Insomnia Disorder according to DSM-5 criteria. *Int J Psychophysiol* 2015;98:435–40.
- Wong ML, Lau KNT, Espie CA. Psychometric properties of the Sleep Condition Indicator and Insomnia Severity Index in the evaluation of insomnia disorder. *Sleep Med* 2017;33:76–81.
- Lin C-Y, Cheng ASK, Imani V, *et al*. Advanced psychometric testing on a clinical screening tool to evaluate insomnia: sleep condition indicator in patients with advanced cancer. *Sleep Biol Rhythms* 2020;18:343–9.
- Luik AI, Machado PF, Siriwardena N. Screening for insomnia in primary care: using a two-item version of the Sleep Condition Indicator. *Br J Gen Pract* 2019;69:79–80.
- Kohl M. MKpower: Power Analysis and Sample Size Calculation, 2023. Available: <https://github.com/stamats/MKpower>

- 21 Hellström A, Hagell P, Broström A, *et al.* A classical test theory evaluation of the Sleep Condition Indicator accounting for the ordinal nature of item response data. *PLoS ONE* 2019;14:e0213533.
- 22 Bayard S, Lebrun C, Arifi-Rossignol A, *et al.* Diagnostic Validity of the Sleep Condition Indicator to Screen for Diagnostic and Statistical Manual-5 Insomnia Disorder in Patients with Parkinson's Disease. *Eur Neurol* 2021;84:333–9.
- 23 Gardani M, Morfiri E, Thomson A, *et al.* Evaluation of Sleep Disorders in Patients With Severe Traumatic Brain Injury During Rehabilitation. *Arch Phys Med Rehabil* 2015;96:1691–7.
- 24 Morin. Insomnia: psychological assessment and management. Guilford Press; 1993.
- 25 Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: validity of a brief depression severity measure. *J Gen Intern Med* 2001;16:606–13.
- 26 Spitzer RL, Kroenke K, Williams JBW, *et al.* A brief measure for assessing generalized anxiety disorder: the GAD-7. *Arch Intern Med* 2006;166:1092–7.
- 27 MacIsaac R, Ali M, Peters M, *et al.* Derivation and Validation of a Modified Short Form of the Stroke Impact Scale. *J Am Heart Assoc* 2016;5:e003108.
- 28 Cronbach LJ. Coefficient alpha and the internal structure of tests. *Psychometrika* 1951;16:297–334.
- 29 Taber KS. The Use of Cronbach's Alpha When Developing and Reporting Research Instruments in Science Education. *Res Sci Educ* 2018;48:1273–96.
- 30 Robin X, Turck N, Hainard A, *et al.* pROC: an open-source package for R and S+ to analyze and compare ROC curves. *BMC Bioinformatics* 2011;12:77.
- 31 Youden WJ. Index for rating diagnostic tests. *Cancer* 1950;3:32–5.
- 32 Mandrekar JN. Receiver operating characteristic curve in diagnostic test assessment. *J Thorac Oncol* 2010;5:1315–6.
- 33 Murad MH, Lin L, Chu H, *et al.* The association of sensitivity and specificity with disease prevalence: analysis of 6909 studies of diagnostic test accuracy. *CMAJ* 2023;195:E925–31.
- 34 Fleming MK, Smejka T, Henderson Slater D, *et al.* Self-Reported and Objective Sleep Measures in Stroke Survivors With Incomplete Motor Recovery at the Chronic Stage. *Neurorehab Neural Repair* 2021;35:851–60.
- 35 Santini A, Man A, Voidăzan S. Accuracy of Diagnostic Tests. *J Crit Care Med (Targu Mures)* 2021;7:241–8.
- 36 Mulherin SA, Miller WC. Spectrum bias or spectrum effect? Subgroup variation in diagnostic test evaluation. *Ann Intern Med* 2002;137:598–602.
- 37 Hertenstein E, Feige B, Gmeiner T, *et al.* Insomnia as a predictor of mental disorders: A systematic review and meta-analysis. *Sleep Med Rev* 2019;43:96–105.
- 38 Hajian-Tilaki K. Sample size estimation in diagnostic test studies of biomedical informatics. *J Biomed Inform* 2014;48:193–204.
- 39 Woodfield R. UK Biobank Stroke Outcomes Group, UK Biobank Follow-up and Outcomes Working Group, Sudlow CLM. Accuracy of Patient Self-Report of Stroke: A Systematic Review from the UK Biobank Stroke Outcomes Group. *PLoS ONE* 2015;10:e0137538.
- 40 Cai H, Wang XP, Yang GY. Sleep Disorders in Stroke: An Update on Management. *Aging Dis* 2021;12:570–85.